Sun YF, Cao XK, Wei Q, Gao YH. Potential biomarkers for the prognosis of gastrointestinal stromal tumors. World J Gastrointest Oncol 2025; 17(4): 102831 [DOI: 10.4251/wjgo.v17.i4.102831]
Corresponding Author of This Article
Yao-Hui Gao, PhD, Professor, Department of Pathology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, No. 301 Yanchang Middle Road, Shanghai 200000, China. gaoyaohui187@tongji.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 102831 Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.102831
Potential biomarkers for the prognosis of gastrointestinal stromal tumors
Yue-Fang Sun, Xuan-Ke Cao, Qing Wei, Yao-Hui Gao
Yue-Fang Sun, Xuan-Ke Cao, Qing Wei, Yao-Hui Gao, Department of Pathology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200000, China
Co-first authors: Yue-Fang Sun and Xuan-Ke Cao.
Co-corresponding authors: Qing Wei and Yao-Hui Gao.
Author contributions: Sun YF, Cao XK, Wei Q and Gao YH designed and performed the research study; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yao-Hui Gao, PhD, Professor, Department of Pathology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, No. 301 Yanchang Middle Road, Shanghai 200000, China. gaoyaohui187@tongji.edu.cn
Received: November 6, 2024 Revised: January 17, 2025 Accepted: February 5, 2025 Published online: April 15, 2025 Processing time: 140 Days and 13.9 Hours
Core Tip
Core Tip: The importance of predicting prognosis in the management of gastrointestinal stromal tumors (GIST) is well known, with a particular focus on mitotic activity, tumor size, anatomical location, and KIT and platelet-derived growth factor receptor alpha mutation status. It underscores the emerging significance of inflammatory markers such as the neutrophil-to-lymphocyte ratio, systemic immune-to-inflammation index, platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) in predicting GIST prognosis and recurrence risk. This study identified the MLR and PLR as independent risk factors, thereby providing a predictive model for recurrence-free survival. However, it is important to note that the study has limitations, including its retrospective design, small sample size, and lack of external validation.
